# Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL

> **NCT05149170** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 30 (estimated)

## Conditions studied

- Early-stage
- Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type

## Interventions

- **DRUG:** Anti-PD-1 monoclonal antibody

## Key facts

- **NCT ID:** NCT05149170
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-01
- **Primary completion:** 2022-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-12-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05149170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05149170, "Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05149170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*